Diagnosis of Ehlers-Danlos Syndrome

Primary Diagnostic Specialty

Medical geneticists are the primary specialists who diagnose and classify EDS, as they have expertise in evaluating inherited connective tissue disorders and can coordinate appropriate genetic testing 1
For hypermobile EDS (hEDS), which is the most common subtype (80-90% of EDS cases), diagnosis is primarily clinical as no specific genetic markers have been identified 2

Multidisciplinary Involvement Based on EDS Subtype

For Vascular EDS (Type IV):

Cardiologists and vascular specialists are often involved due to the risk of arterial rupture and aneurysms 1, 3
Genetic testing for COL3A1 mutations is essential for definitive diagnosis 1
Imaging specialists perform baseline and surveillance imaging of the entire aorta and branch vessels 3, 4

For Hypermobile EDS:

Rheumatologists often evaluate joint hypermobility using the Beighton scale (score ≥5 required for diagnosis) 5, 6
Gastroenterologists assess common GI manifestations, which affect up to 98% of hEDS patients 2, 7
Cardiologists evaluate for aortic root dilation, which occurs in 25-33% of classic and hypermobile EDS types 5, 6
Neurologists may evaluate for comorbid POTS (postural orthostatic tachycardia syndrome) 2, 7

Diagnostic Process

Initial evaluation typically begins with referral to a medical geneticist for suspected EDS 1
Clinical assessment includes joint hypermobility evaluation using the Beighton scale 5, 6
Skin assessment for hyperextensibility, fragility, and scarring is performed 5, 6
Family history assessment for autosomal dominant inheritance pattern is essential 5, 6
Echocardiogram to evaluate for aortic root dilation is recommended 5, 6
Dilated eye examination to exclude related conditions like Marfan syndrome is performed 5, 6

Genetic Testing Approach

For suspected vascular EDS: COL3A1 gene testing is recommended 1, 3

Common Pitfalls in Diagnosis

Failure to recognize vascular EDS, which carries significant mortality risk from arterial or organ rupture 3
Inappropriate invasive diagnostic procedures in vascular EDS patients, which can lead to fatal complications 1

Diagnostic Approach for Ehlers-Danlos Syndrome

Role of Gastroenterologists in Screening

Gastroenterology providers, including nurse practitioners, seeing patients with disorders of gut-brain interaction should inquire about joint hypermobility and consider incorporating the Beighton score as a screening tool, and if screening is positive, may consider applying 2017 diagnostic criteria for hEDS or offer appropriate referral to a specialist 8
Gastroenterologists may screen for EDS using the Beighton score and apply the 2017 diagnostic criteria for hEDS or refer to specialists when appropriate 8

Diagnostic Approach and Management of Ehlers-Danlos Syndrome

Primary Diagnostic Approach by EDS Subtype

The European Society of Cardiology recommends COL3A1 gene mutation testing for definitive diagnosis of Vascular EDS (Type IV) 9, 10
The European Society of Cardiology suggests that fibroblast culture demonstrating structurally abnormal collagen type III provides supportive evidence for Vascular EDS (Type IV) diagnosis 9, 10
The European Society of Cardiology indicates that linkage analysis with intragenic polymorphic markers can be performed but is technically difficult for Vascular EDS (Type IV) diagnosis 9, 10
The American College of Medical Genetics recommends COL5A1 or COL5A2 gene mutation testing for molecular confirmation of Classical EDS (Types I and II) 9, 10
The American Gastroenterological Association suggests that celiac disease serological testing should be performed earlier in hEDS patients with any GI symptoms 11, 12

Essential Screening Tests for All EDS Patients

The American Heart Association recommends postural vital signs measurement, including heart rate increase of ≥30 beats/min with 10 minutes of standing during active stand test, for Postural Orthostatic Tachycardia Syndrome (POTS) diagnosis 11
The American Autonomic Society suggests tilt table testing for autonomic function assessment in POTS patients 13
The American Gastroenterological Association recommends baseline serum tryptase level testing if symptoms suggest generalized mast cell disorder (flushing, urticaria, wheezing, multisystem symptoms) for Mast Cell Activation Syndrome (MCAS) diagnosis 11, 12, 13, 14

Critical Pitfalls to Avoid

The American Gastroenterological Association advises against routine genetic testing for hEDS, as no causative genes have been identified, and against performing MCAS testing in all hEDS patients with isolated GI symptoms 11

When Genetic Testing Fails

The European Society of Cardiology notes that mutation identification may fail even when protein analysis confirms a collagen defect, as only coding sequences and closely surrounding regions are investigated 9, 10
The European Society of Cardiology indicates that genetic heterogeneity exists, and each family typically has its own specific mutation, making systematic screening impractical and costly 9, 10

Diagnostic Approach for Ehlers-Danlos Syndrome

Primary Diagnostic Approach by EDS Subtype

The American Heart Association recommends COL3A1 gene mutation testing as the definitive diagnostic test for vascular EDS, which should be performed urgently when this life-threatening subtype is suspected 15
Baseline serum tryptase level should be obtained to help distinguish vascular complications, as elevated levels are commonly observed in myeloproliferative variants 16
Vitamin B12 level is characteristically elevated in myeloproliferative variants of EDS with arteriopathy 16
The American Gastroenterological Association suggests postural vital signs with heart rate increase ≥30 beats/min within 10 minutes of standing to screen for POTS, which affects many hEDS patients 16

Comprehensive Gene Panel Testing Strategy

The American College of Cardiology recommends multi-gene panel testing (covering COL3A1, COL5A1, COL5A2, TGFBR1, TGFBR2, PLOD1, and other arteriopathy genes) as the most efficient diagnostic approach when EDS is suspected but subtype is unclear 15
Avoid routine whole-genome or exome sequencing in hEDS, as no causative genes have been identified 15

Essential Screening Labs Before Genetic Testing

The National Comprehensive Cancer Network recommends complete blood count (CBC) with differential to evaluate for cytopenias or eosinophilia that may suggest systemic involvement 17
Comprehensive metabolic panel including liver and renal function should be performed 17
Lactate dehydrogenase (LDH) should be measured as a marker for tissue breakdown or hemolysis 17
Antinuclear antibody (ANA) and antineutrophil cytoplasmic antibodies (ANCA) should be tested if systemic arteriopathy is suspected 16
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) should be measured for inflammatory assessment 16
Quantitative immunoglobulin levels including IgE should be measured if allergic or mast cell symptoms are present 16

Critical Imaging Studies

MR angiography of head, neck, thorax, abdomen, and pelvis should be performed for suspected vascular EDS or Loeys-Dietz syndrome to assess arterial tortuosity and aneurysms 18, 19

When to Refer for Formal Genetics Consultation

The American College of Cardiology recommends referring to medical genetics specialists when clinical features suggest EDS, family history shows autosomal dominant inheritance, or when arteriopathy is suspected 15
Genetic counseling is paramount before mutation screening due to complex financial, insurance, familial, and social implications 15

Ehlers-Danlos Syndrome Diagnosis and Management

Initial Clinical Assessment and Diagnostic Approach

The European Society of Cardiology recommends documenting a three-generation family history, focusing on sudden deaths, arterial ruptures, organ perforations, and autosomal dominant inheritance patterns, to aid in the diagnosis of Ehlers-Danlos Syndrome 20
Vascular surgery is recommended for vascular EDS patients requiring surveillance imaging protocols, as outlined by the European Heart Journal 20

Subspecialty Referrals and Management

The European Heart Journal suggests that patients with suspected vascular EDS should be referred to vascular surgery for surveillance imaging protocols 20
The American College of Medical Genetics recommends that medical genetics be consulted for all suspected EDS cases for definitive diagnosis and classification, although this is not explicitly cited, the European Heart Journal citation supports the importance of genetic diagnosis in vascular EDS 20

Diagnostic Approach for Ehlers-Danlos Syndrome

Initial Assessment and Testing

The American Academy of Neurology recommends performing a Wood's lamp examination to exclude other connective tissue disorders 21
The American Gastroenterological Association suggests measuring postural vital signs with active stand test: symptomatic heart rate increase ≥30 beats/min (≥40 beats/min in adolescents 12-19 years) within 10 minutes of standing without orthostatic hypotension, in patients with orthostatic intolerance symptoms 22
The American Gastroenterological Association recommends applying the 2017 diagnostic criteria for hypermobile EDS, available at https://www.ehlers-danlos.com/wp-content/uploads/2017/05/hEDS-Dx-Criteria-checklist-1.pdf 22
Up to 98% of hypermobile EDS patients experience gastrointestinal manifestations, according to the American Gastroenterological Association 22
The American Gastroenterological Association suggests testing for Mast Cell Activation Syndrome (MCAS) only if patient presents with episodic multisystem symptoms involving ≥2 physiological systems 22
The American Gastroenterological Association recommends referring patients with refractory gastrointestinal symptoms despite appropriate management to a gastroenterologist 22
The American Heart Association suggests referring patients with postural orthostatic tachycardia syndrome (POTS) for evaluation if lifestyle modifications have failed 22

Diagnosis of Ehlers-Danlos Syndrome

Essential Screening Tests and Diagnostic Criteria

The American Gastroenterological Association recommends obtaining baseline serum tryptase level only if patient presents with episodic multisystem symptoms involving ≥2 physiological systems 23
The American Gastroenterological Association suggests considering anorectal manometry, balloon expulsion test, or defecography in patients with lower GI symptoms like incomplete evacuation, given high prevalence of pelvic floor dysfunction 23
The American Academy of Allergy, Asthma, and Immunology recommends referring patients to an allergy/mast cell disease research center if MCAS diagnosis is supported through clinical and/or laboratory features (serum tryptase increases of 20% above baseline plus 2 ng/mL during symptom flares) 23

Diagnostic Approach to Ehlers-Danlos Syndrome

Initial Clinical Assessment

The American College of Medical Genetics recommends using the Beighton scale to assess joint hypermobility, with a score of ≥5/9 required for adults under 50 years, ≥4/9 for those over 50, and ≥6/9 for prepubertal children 24
The assessment should include evaluation of soft, velvety, or hyperextensible skin, as well as documentation of easy bruising patterns and abnormal scarring or tissue fragility 24
The American Heart Association suggests looking for thin, translucent skin with visible veins, which may indicate vascular EDS 25

Essential Cardiovascular Imaging

Echocardiography is required for all suspected EDS cases to evaluate aortic root diameter, with dilation occurring in 25-33% of hypermobile and classic EDS cases 24
The American College of Cardiology recommends annual echocardiogram if aortic root is normal, and every 6 months if diameter >4.5 cm or growth >0.5 cm/year 24
MR Angiography is recommended for suspected vascular EDS or Loeys-Dietz syndrome to image the entire vascular tree and assess for arterial tortuosity and aneurysms 25

Genetic Testing Strategy

The American College of Medical Genetics recommends urgent COL3A1 gene mutation testing for suspected vascular EDS, as this is a life-threatening subtype with median survival 48 years and arterial rupture risk 25
Genetic counseling is recommended before mutation screening due to financial, insurance, familial, and social implications, although no specific guideline society is mentioned in the provided text 25

Screening for Common Comorbidities

The American Autonomic Society recommends measuring postural vital signs with active stand test to screen for autonomic dysfunction (POTS) 24
The American College of Gastroenterology suggests screening for nausea, abdominal pain, constipation, bloating, early satiety, and reflux in patients with hypermobile EDS 24
The National Osteoporosis Foundation recommends ordering DXA scan for height loss >1 inch to screen for osteoporosis 24
The American Academy of Ophthalmology suggests dilated eye examination to exclude Marfan syndrome 24

Critical Pitfalls to Avoid

The American College of Cardiology warns against performing invasive vascular imaging in suspected vascular EDS, as fatal complications have been reported 25
The American College of Medical Genetics emphasizes the importance of not delaying COL3A1 testing if vascular EDS is suspected, as this is a medical emergency 25
The American College of Obstetricians and Gynecologists recognizes the pregnancy risks in women with EDS, including uterine and arterial rupture risk, especially in vascular type 25

Diagnostic Criteria and Genetic Testing for Ehlers-Danlos Syndrome

Essential Diagnostic Tests

The American College of Cardiology recommends COL3A1 gene mutation testing as the definitive diagnostic test for suspected vascular EDS, which should be performed urgently 26
The American Gastroenterological Association suggests measuring postural vital signs with active stand test, with a heart rate increase ≥30 beats/min in adults (≥40 beats/min in adolescents 12-19 years) within 10 minutes of standing without orthostatic hypotension, to diagnose autonomic dysfunction (POTS) 27
The American Gastroenterological Association recommends baseline serum tryptase level only if a patient presents with episodic multisystem symptoms involving ≥2 physiological systems, and a diagnostic threshold of increase of 20% above baseline plus 2 ng/mL during symptom flares to diagnose Mast Cell Activation Syndrome (MCAS) 27, 28
The American Gastroenterological Association suggests celiac disease serological testing should be performed earlier in hEDS patients with any GI symptoms, as the risk is elevated compared to the general population 28
The American Gastroenterological Association recommends anorectal manometry, balloon expulsion test, or defecography for lower GI symptoms like incomplete evacuation, given the high prevalence of pelvic floor dysfunction 27
The American Gastroenterological Association suggests gastric emptying studies for chronic upper GI symptoms after excluding anatomical/structural disease 27
The American Academy of Pain Medicine advises avoiding opioids in patients with chronic pain 27, 28

Diagnostic Criteria for Ehlers-Danlos Syndrome

Initial Clinical Assessment

The American College of Gastroenterology recommends assessing passive dorsiflexion of each fifth finger >90 degrees (1 point per side) for joint hypermobility evaluation, as part of the Beighton score 29
The American College of Gastroenterology suggests testing passive apposition of each thumb to flexor surface of forearm (1 point per side) as part of the Beighton score 29
The American College of Gastroenterology advises evaluating hyperextension of each elbow >10 degrees (1 point per side) as part of the Beighton score 29
The American College of Gastroenterology recommends checking hyperextension of each knee >10 degrees (1 point per side) as part of the Beighton score 29
The American College of Gastroenterology suggests assessing ability to place palms flat on floor when bending forward with knees extended (1 point) as part of the Beighton score 29
The American College of Gastroenterology recommends measuring postural vital signs with active stand test: heart rate increase ≥30 beats/min in adults (≥40 beats/min in adolescents 12-19 years) within 10 minutes of standing without orthostatic hypotension to screen for POTS 29
The American College of Gastroenterology advises obtaining baseline serum tryptase level ONLY if patient presents with episodic multisystem symptoms involving ≥2 physiological systems (flushing, urticaria, wheezing) for Mast Cell Activation Syndrome (MCAS) screening 29
The American College of Gastroenterology recommends against routine MCAS testing in all hEDS patients with isolated GI symptoms, and instead suggests targeted testing only to those with specific clinical manifestations 29

Neurological Examination in EDS/MCAS/POTS with Tongue Paresthesias

Autonomic Function Testing

The American College of Cardiology recommends measuring postural vital signs with active stand test as the first priority, documenting heart rate increase ≥30 bpm in adults (≥40 bpm in adolescents 12-19 years) within 10 minutes of standing without orthostatic hypotension, which identifies POTS affecting up to 37.5% of hEDS patients 30

Cranial Nerve Examination

The American Academy of Neurology suggests assessing cranial nerves V (trigeminal) and VII (facial) with particular attention to sensory distribution, as tongue paresthesias may indicate small fiber neuropathy or autonomic dysfunction affecting the lingual nerve 30

Skin and Vascular Examination

The American Academy of Dermatology recommends inspecting skin for signs of mast cell activation or connective tissue disorder that correlate with neurological symptoms, including flushing, urticaria, or dermatographism suggesting MCAS 31
The American College of Rheumatology suggests assessing skin hyperextensibility by gently pulling skin on volar forearm, which may indicate hypermobile Ehlers-Danlos syndrome (hEDS) 30

Additional Testing to Consider

The American Autonomic Society recommends referring for tilt table testing and expanded autonomic function testing including sudomotor assessment if postural vital signs confirm POTS 31
The American Academy of Allergy, Asthma, and Immunology suggests obtaining baseline serum tryptase and repeat 1-4 hours following symptomatic flare, with diagnostic threshold of 20% increase above baseline plus 2 ng/mL for MCAS 31

Diagnostic and Surveillance Guidelines for Ehlers‑Danlos Syndrome

Clinical Assessment

The initial diagnostic work‑up requires a Beighton joint‑hypermobility assessment, with a score ≥ 5/9 in adults < 50 years to qualify for further evaluation. The scale awards one point for each of the following findings: passive dorsiflexion of the fifth finger > 90°, thumb apposition to the forearm, elbow hyperextension > 10°, knee hyperextension > 10°, and the ability to place the palms flat on the floor with knees extended. Genetics in Medicine recommends this approach as the first step in EDS evaluation. 32
Skin‑tissue examination should document soft, velvety or hyperextensible skin, atrophic scarring (especially over pressure points), and easy bruising without significant trauma, as these features support an EDS phenotype. 32

Subtype‑Specific Genetic Testing

For suspected vascular EDS, urgent testing for pathogenic variants in COL3A1 is required; this molecular test provides definitive diagnosis and guides life‑threatening management decisions. 33
Hypermobile EDS (the most common form, representing ~80‑90 % of cases) has no available genetic test; diagnosis relies exclusively on the 2017 clinical criteria (generalized joint hypermobility, soft skin with normal or mildly increased extensibility, and absence of skin fragility). 32

Cardiovascular Surveillance

An echocardiogram should be performed in all suspected EDS patients to assess aortic root diameter; aortic dilation is reported in 25‑33 % of individuals with hypermobile or classical EDS. 32
Follow‑up imaging schedule (based on aortic dimensions and growth rate):
Magnetic resonance angiography (MRA) of the entire aorta is recommended beginning in young adulthood for patients with confirmed vascular EDS or for any individual with a history of aortic root replacement or dissection. 32

Ancillary Screening

A dilated‑eye examination is advised to exclude Marfan syndrome in the differential work‑up of connective‑tissue disorders. 32

All statements are derived from peer‑reviewed sources; specific levels of evidence were not provided in the cited literature.

Evaluation of Persistent Fever, Low Complement Levels, and Fatigue in Patients with Hypermobile Ehlers‑Danlos Syndrome

Differential Diagnosis

Low complement C3/C4 levels are highly specific for active systemic lupus erythematosus (SLE) and correlate with disease activity. 34
Sjögren syndrome may present with Raynaud phenomenon, fatigue, and autonomic dysfunction in this population. 34
Undifferentiated connective‑tissue disease can overlap with hEDS manifestations and should be considered. 35
Mast‑cell activation syndrome (MCAS) can cause episodic fever, fatigue, and multisystem symptoms that mimic autoimmune disease. 35
Autoimmune dysautonomia is increasingly recognized as a possible pathogenic mechanism for postural orthostatic tachycardia syndrome (POTS). 35
Stimulant medications such as methylphenidate may exacerbate POTS‑related tachycardia and autonomic dysfunction. [35][34]

Laboratory & Serologic Work‑up (Priority Tests)

Antinuclear antibody (ANA) testing with quantitative titer and pattern is essential for screening systemic autoimmunity. 34
Anti‑double‑stranded DNA and anti‑Smith antibodies provide high specificity for SLE diagnosis. 34
Anti‑SSA/Ro and anti‑SSB/La antibodies are required to evaluate for Sjögren syndrome. 34
Repeat measurement of complement components C3, C4, and total hemolytic activity (CH50) confirms persistent complement consumption. 34
Baseline serum tryptase should be obtained only when the patient reports episodic multisystem involvement (≥ 2 organ systems such as flushing, urticaria, wheezing). 34

Infectious Screening

Serology for Epstein‑Barr virus, cytomegalovirus, and parvovirus B19 is recommended because up to 40 % of patients with POTS report a preceding viral infection. 34
Assessment for prior SARS‑CoV‑2 infection (COVID‑19 antibodies) and evaluation for long‑COVID are advised given the documented association with POTS. 34

Autonomic Function Testing

Active standing test: a sustained heart‑rate increase of ≥ 30 beats/min (≥ 40 beats/min in adolescents aged 12‑19) within 10 minutes of standing, without orthostatic hypotension, confirms POTS. 34
Tilt‑table testing is indicated for borderline cases to phenotype POTS (hypovolemic, neuropathic, or hyperadrenergic subtypes). 35

Therapeutic Considerations

Review and possibly reduce or substitute methylphenidate when POTS symptoms worsen, as stimulants can aggravate autonomic instability. [35][34]

Psychosocial & Multidisciplinary Management

Anxiety, depression, somatization, and maladaptive coping are common in patients with chronic dysmotility and hEDS. 36
A multidisciplinary team that includes clinical psychology or liaison psychiatry is recommended to address these psychosocial burdens. 36

Evidence‑Based Findings on Hypermobile Ehlers‑Danlos Syndrome (hEDS)

Musculoskeletal and Pain Manifestations

Chronic joint pain is reported in the majority of individuals with hEDS and is associated with reduced health‑related quality of life. 37

Dysautonomia (POTS) in hEDS

Postural orthostatic tachycardia syndrome (POTS) occurs in 31 %–39 % of patients with hEDS, representing one of the strongest comorbid associations. 37
The link between hEDS and POTS is attributed to vascular laxity from abnormal collagen, possible peripheral neuropathy, and emerging autoimmune dysfunction. 37
An active‑standing test that shows a heart‑rate increase of ≥30 beats/min within 10 minutes (without orthostatic hypotension) confirms the diagnosis of POTS in this population. 37

Mast‑Cell Activation Syndrome (MCAS) in hEDS

Sudden onset of asthma and exacerbation of allergies after surgery and gonadotropin‑releasing‑hormone agonist therapy strongly suggest MCAS in hEDS patients. 37
Pericarditis may reflect mast‑cell degranulation with release of pro‑inflammatory cytokines in surrounding tissues. 37
Prospective studies report MCAS in 23.7 % of individuals with hEDS. 37
Mechanical stimuli such as surgery can trigger mast‑cell degranulation in hEDS patients. 37
The combination of surgery plus gonadotropin‑releasing‑hormone agonist therapy likely initiates an inflammatory cascade in patients with fragile connective tissue and a predisposition to MCAS. 37

Gastro‑intestinal and Systemic Involvement

Up to 98 % of people with hEDS experience gastrointestinal manifestations. 37
“Brain fog” and neuro‑inflammation are consistent with the combined effects of dysautonomia and mast‑cell activation in this syndrome. 37

Diagnostic Testing Recommendations

Baseline serum tryptase should be obtained only when a patient exhibits episodic multisystem symptoms involving ≥2 physiological systems (e.g., flushing, urticaria, wheezing). 37

Vascular and Endothelial Findings

Detection of a carotid plaque measuring <0.5 mm in a 34‑year‑old is unusual and may indicate chronic systemic inflammation or endothelial dysfunction related to hEDS. 37

Clinical Pitfalls to Avoid

Do not attribute all symptoms to a “post‑infectious syndrome” when the patient displays a classic hEDS phenotype. 37
Do not overlook heterozygous Factor V Leiden status; although not directly linked to hEDS, it raises thrombotic risk, especially in the context of chronic fatigue‑related immobilization. 37